Metropolis Healt

Why is Metropolis Healthcare Ltd falling/rising?

As of 22-Jun, Metropolis Healthcare Ltd's stock is experiencing a decline of 2.04% today, despite strong long-term performance. The drop is attributed to reduced investor participation and current market conditions, overshadowing recent financial growth.

As of 22-Jun, Metropolis Healthcare Ltd's stock price is currently falling, as indicated by a change of -11.25, which represents a decrease of 2.04%. Despite a positive performance over the longer term, where the stock has shown a year-to-date increase of 12.16% and a one-year increase of 27.31%, today's performance has underperformed the sector by 2.51%. <BR><BR>The stock touched an intraday low of Rs 526.65, reflecting a significant decline of 4.63% during the day. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 12.18% against the five-day average. This decline in trading activity may contribute to the downward pressure on the stock price.<BR><BR>While the company has demonstrated strong financial performance in recent quarters, including a 63.49% growth in profit after tax and a 24.33% increase in net sales, the current market conditions and reduced trading volume appear to be influencing the stock's price negatively today.

Which are the latest news on Metropolis Healt?

What does Metropolis Healt do?

Metropolis Healthcare Ltd is a small-cap company in the healthcare services industry, primarily focused on pathology, with recent net sales of 425 Cr and a net profit of 51 Cr for the quarter ending March 2026. Key financial metrics include a P/E ratio of 55.00 and a market cap of INR 10,997 Cr.

Overview:<BR>Metropolis Healthcare Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company commenced its pathology business in January 1980 and has undergone various partnership changes. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 425 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 51 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 10,997 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.37% <BR>Debt-Equity: 0.02 <BR>Return on Equity: 13.00% <BR>Price to Book: 7.32 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Metropolis Healt?

As of 10th June, Metropolis Healthcare Ltd has a market capitalization of 10,997.00 Cr, with recent net sales of 1,645.84 Cr and a net profit of 190.02 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Metropolis Healthcare Ltd has a market capitalization of 10,997.00 Cr, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,645.84 Cr, while the sum of Net Profit for the same period stands at 190.02 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 1,330.97 Cr, and Total Assets amount to 1,859.09 Cr.

Who are in the management team of Metropolis Healt?

The management team of Metropolis Health includes Sushil Kanubhai Shah (Chairman & Executive Director), Ameera Sushil Shah (Managing Director), and several independent directors: Vivek Gambhir, Sanjay Bhatnagar, Milind Shripad Sarwate, and Anita Ramachandran, along with Hemant Sachdev (Non-Executive Director) and Neha Shah (Company Secretary). They oversee the company's operations and strategic direction.

The management team of Metropolis Health includes the following key individuals:<BR><BR>1. **Sushil Kanubhai Shah** - Chairman & Executive Director<BR>2. **Ameera Sushil Shah** - Managing Director<BR>3. **Vivek Gambhir** - Independent Director<BR>4. **Sanjay Bhatnagar** - Independent Director<BR>5. **Milind Shripad Sarwate** - Independent Director<BR>6. **Anita Ramachandran** - Independent Director<BR>7. **Hemant Sachdev** - Non-Executive & Non-Independent Director<BR>8. **Neha Shah** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Metropolis Healt?

Metropolis Healt's peers include Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost. Thyrocare Tech. leads with a 1-year return of 61.52%, while Metropolis Healt has a return of 23.96%, significantly higher than Syngene Intl.'s -31.36%.

Peers: The peers of Metropolis Healt are Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest. Average management risk is present at Indegene, Vimta Labs, and Krsnaa Diagnost., while Below Average management risk is noted at Suven Life Scie. Growth is uniformly Below Average across all peers. Excellent capital structure is seen at Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Vimta Labs, and Krsnaa Diagnost., while Indegene and Suven Life Scie. have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Thyrocare Tech. at 61.52%, while Syngene Intl. has the lowest at -31.36%. Metropolis Healt's 1-year return of 23.96% is significantly higher than Syngene Intl.'s. Additionally, Suven Life Scie. and Krsnaa Diagnost. are among the peers whose six-month return is negative.

Has Metropolis Healthcare Ltd declared dividend?

Yes, Metropolis Healthcare Ltd has declared a 50% dividend, amounting to ₹4 per share, with an ex-date of November 11, 2025. The company has shown strong total returns, particularly a 31.75% return over the past year.

Metropolis Healthcare Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 4<BR>- Ex-date: Nov-11-2025<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was 8.88%, the dividend return was 0.21%, resulting in a total return of 9.09%.<BR><BR>Over the last 6 months, the price return was 7.45%, the dividend return was 0.20%, leading to a total return of 7.65%.<BR><BR>For the past year, the price return was 30.55%, the dividend return was 1.20%, culminating in a total return of 31.75%.<BR><BR>In the last 2 years, the price return was 14.78%, the dividend return was 1.01%, which resulted in a total return of 15.79%.<BR><BR>Over the past 3 years, the price return was 57.85%, the dividend return was 2.76%, yielding a total return of 60.61%.<BR><BR>In the last 4 years, the price return was 5.12%, the dividend return was 4.23%, leading to a total return of 9.35%.<BR><BR>For the past 5 years, the price return was -9.21%, the dividend return was 3.37%, resulting in a total return of -5.84%.<BR><BR>Overall, Metropolis Healthcare Ltd has declared a significant dividend while also demonstrating strong total returns over various periods, particularly in the last year and three years, indicating a positive trend for investors.

Are Metropolis Healthcare Ltd latest results good or bad?

Metropolis Healthcare Ltd's Q4 FY26 results are strong, with a net profit of ₹50.90 crores (up 74.67% year-on-year) and revenue of ₹424.68 crores (up 22.99%). The operating margin improved to 25.44%, indicating enhanced efficiency, though investors should watch for rising interest costs and the sustainability of this growth.

Metropolis Healthcare Ltd's latest results for Q4 FY26 can be considered quite strong. The company reported a net profit of ₹50.90 crores, which represents a remarkable year-on-year increase of 74.67%. Additionally, revenue for the quarter reached ₹424.68 crores, marking a 22.99% increase compared to the same period last year. <BR><BR>One of the standout features of this quarter was the operating margin, which improved to 25.44%, the highest recorded in the past eight quarters. This indicates enhanced operational efficiency and pricing power. Furthermore, the company showed a sequential recovery from the previous quarter, with net profit and revenue both increasing quarter-on-quarter.<BR><BR>Overall, the results reflect a positive turnaround for Metropolis Healthcare, showcasing strong growth in both profit and revenue, alongside improved margins. However, investors should also be aware of rising interest costs and the need to monitor the sustainability of this growth moving forward.

Should I buy, sell or hold Metropolis Healthcare Ltd?

When is the next results date for Metropolis Healthcare Ltd?

The next results date for Metropolis Healthcare Ltd is 13 May 2026.

The next results date for Metropolis Healthcare Ltd is scheduled for 13 May 2026.

What is the bonus history of Metropolis Healt?

Metropolis Healthcare Ltd recently announced a 3:1 bonus issue, with an ex-date of March 20, 2026, meaning shareholders will receive three additional shares for every one share held.

Metropolis Healthcare Ltd has a recent bonus issue where they announced a 3:1 bonus. The ex-date for this bonus is set for March 20, 2026. This means that for every one share held, shareholders will receive three additional shares. If you have any further questions about the company or its financial actions, feel free to ask!

Is Metropolis Healt technically bullish or bearish?

As of December 4, 2025, Metropolis Health's technical trend is neutral with mixed signals, showing a mildly bearish outlook on weekly and monthly Bollinger Bands, while daily moving averages indicate a slight bullish trend, reflecting overall lack of strong momentum.

As of 4 December 2025, the technical trend for Metropolis Healt has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are both mildly bearish, while the monthly MACD remains bullish. The Bollinger Bands indicate a bearish outlook on both weekly and monthly charts. Daily moving averages show a mildly bullish trend, but the overall indicators suggest a lack of strong momentum. The Dow Theory reflects a mildly bearish sentiment on the weekly chart and bullish on the monthly. Given the recent price action, including a decline from the previous close, the technical stance remains neutral with a slight bearish inclination in the short term.

How has been the historical performance of Metropolis Healt?

Metropolis Healt has shown consistent growth in net sales and profitability, with net sales increasing from 761.18 Cr in March 2019 to 1,331.20 Cr in March 2025, and profit after tax reaching 145.51 Cr in the same period. The company's total assets and liabilities have also significantly grown, reflecting a robust financial performance.

Answer:<BR>The historical performance of Metropolis Healt shows a consistent growth in net sales and profitability over the years, with a notable increase in the most recent fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Metropolis Healt's net sales have risen from 761.18 Cr in March 2019 to 1,331.20 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, reaching 1,331.20 Cr in March 2025, up from 761.18 Cr in March 2019. The company's total expenditure has also increased, amounting to 1,028.21 Cr in March 2025, compared to 560.81 Cr in March 2019. Operating profit, excluding other income, has shown fluctuations but reached 302.99 Cr in March 2025, while profit before tax was recorded at 190.85 Cr. The profit after tax for March 2025 was 145.51 Cr, indicating a steady profitability despite some variations in previous years. The company's total assets have grown significantly from 738.33 Cr in March 2020 to 1,859.09 Cr in March 2025, while total liabilities increased from 738.33 Cr to 1,859.09 Cr in the same period. Cash flow from operating activities has remained relatively stable, with 262.00 Cr in March 2025, although the net cash outflow was recorded at -23.00 Cr. Overall, Metropolis Healt has demonstrated a robust growth pattern in revenue and profitability, alongside an increase in assets and liabilities over the years.

Is Metropolis Healt overvalued or undervalued?

As of September 8, 2025, Metropolis Health is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 73.15, an EV to EBITDA ratio of 35.71, and a PEG ratio of 7.47, despite outperforming the Sensex over three years.

As of 8 September 2025, the valuation grade for Metropolis Health has moved from very expensive to expensive, indicating a slight easing in perceived overvaluation. The company is currently considered overvalued based on its high valuation metrics, including a PE ratio of 73.15, an EV to EBITDA ratio of 35.71, and a PEG ratio of 7.47. <BR><BR>In comparison to its peers, Metropolis Health's PE ratio is notably higher than Apollo Hospitals at 71.12 and Narayana Hrudaya at 46.06, both of which are also categorized as expensive. The company's recent stock performance has shown a 1-week decline of 0.79%, contrasting with a 0.53% gain in the Sensex, although it has outperformed the index over a 3-year period with a return of 45.26% compared to the Sensex's 35.35%. Overall, Metropolis Health appears to be overvalued in the current market environment.

Who are the top shareholders of the Metropolis Healt?

The top shareholders of Metropolis Health include Metz Advisory LLP with 30.29%, mutual funds holding 26.42% (led by HDFC Mutual Fund at 9.64%), foreign institutional investors at 15.29%, and individual investors at 3.84%.

The top shareholders of Metropolis Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Metz Advisory LLP holding the highest stake at 30.29%. Mutual funds collectively hold 26.42% of the company, with HDFC Mutual Fund - HDFC Focused 30 Fund being the largest public shareholder at 9.64%. Additionally, FIIs own 15.29% of the shares, while individual investors hold 3.84%.